Literature DB >> 27558423

Adoptive Transfer of Engineered Rhesus Simian Immunodeficiency Virus-Specific CD8+ T Cells Reduces the Number of Transmitted/Founder Viruses Established in Rhesus Macaques.

Victor I Ayala1, Matthew T Trivett1, Eugene V Barsov1, Sumiti Jain1, Michael Piatak1, Charles M Trubey1, W Gregory Alvord2, Elena Chertova1, James D Roser1, Jeremy Smedley1, Alexander Komin1, Brandon F Keele1, Claes Ohlen1, David E Ott3.   

Abstract

AIDS virus infections are rarely controlled by cell-mediated immunity, in part due to viral immune evasion and immunodeficiency resulting from CD4+ T-cell infection. One likely aspect of this failure is that antiviral cellular immune responses are either absent or present at low levels during the initial establishment of infection. To test whether an extensive, timely, and effective response could reduce the establishment of infection from a high-dose inoculum, we adoptively transferred large numbers of T cells that were molecularly engineered with anti-simian immunodeficiency virus (anti-SIV) activity into rhesus macaques 3 days following an intrarectal SIV inoculation. To measure in vivo antiviral activity, we assessed the number of viruses transmitted using SIVmac239X, a molecularly tagged viral stock containing 10 genotypic variants, at a dose calculated to transmit 12 founder viruses. Single-genome sequencing of plasma virus revealed that the two animals receiving T cells expressing SIV-specific T-cell receptors (TCRs) had significantly fewer viral genotypes than the two control animals receiving non-SIV-specific T cells (means of 4.0 versus 7.5 transmitted viral genotypes; P = 0.044). Accounting for the likelihood of transmission of multiple viruses of a particular genotype, the calculated means of the total number of founder viruses transmitted were 4.5 and 14.5 in the experimental and control groups, respectively (P = 0.021). Thus, a large antiviral T-cell response timed with virus exposure can limit viral transmission. The presence of strong, preexisting T-cell responses, including those induced by vaccines, might help prevent the establishment of infection at the lower-exposure doses in humans that typically transmit only a single virus. IMPORTANCE: The establishment of AIDS virus infection in an individual is essentially a race between the spreading virus and host immune defenses. Cell-mediated immune responses induced by infection or vaccination are important contributors in limiting viral replication. However, in human immunodeficiency virus (HIV)/SIV infection, the virus usually wins the race, irreversibly crippling the immune system before an effective cellular immune response is developed and active. We found that providing an accelerated response by adoptively transferring large numbers of antiviral T cells shortly after a high-dose mucosal inoculation, while not preventing infection altogether, limited the number of individual viruses transmitted. Thus, the presence of strong, preexisting T-cell responses, including those induced by vaccines, might prevent infection in humans, where the virus exposure is considerably lower.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27558423      PMCID: PMC5068542          DOI: 10.1128/JVI.01522-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  Vaccine-induced T cells control reversion of AIDS virus immune escape mutants.

Authors:  Caroline S Fernandez; Miranda Z Smith; C Jane Batten; Robert De Rose; Jeanette C Reece; Erik Rollman; Vanessa Venturi; Miles P Davenport; Stephen J Kent
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

3.  Adoptive transfer of lymphocytes isolated from simian immunodeficiency virus SIVmac239Δnef-vaccinated macaques does not affect acute-phase viral loads but may reduce chronic-phase viral loads in major histocompatibility complex-matched recipients.

Authors:  Justin M Greene; Jennifer J Lhost; Paul J Hines; Matthew Scarlotta; Max Harris; Benjamin J Burwitz; Melisa L Budde; Dawn M Dudley; Ngoc Pham; Brian Cain; Caitlin E Mac Nair; Madelyn K Weiker; Shelby L O'Connor; Thomas C Friedrich; David H O'Connor
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

4.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.

Authors:  S R Riddell; P D Greenberg
Journal:  J Immunol Methods       Date:  1990-04-17       Impact factor: 2.303

5.  African green monkey TRIM5α restriction in simian immunodeficiency virus-specific rhesus macaque effector CD4 T cells enhances their survival and antiviral function.

Authors:  Sumiti Jain; Matthew T Trivett; Victor I Ayala; Claes Ohlen; David E Ott
Journal:  J Virol       Date:  2015-02-04       Impact factor: 5.103

6.  Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.

Authors:  Daria J Hazuda; Steven D Young; James P Guare; Neville J Anthony; Robert P Gomez; John S Wai; Joseph P Vacca; Larry Handt; Sherri L Motzel; Hilton J Klein; Geethanjali Dornadula; Robert M Danovich; Marc V Witmer; Keith A A Wilson; Lynda Tussey; William A Schleif; Lori S Gabryelski; Lixia Jin; Michael D Miller; Danilo R Casimiro; Emilio A Emini; John W Shiver
Journal:  Science       Date:  2004-07-08       Impact factor: 47.728

7.  Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous Simian Immunodeficiency Virus-specific CD8(+) T cell clones during acute and chronic infection of rhesus macaques.

Authors:  Diane L Bolton; Jacob T Minang; Matthew T Trivett; Kaimei Song; Jennifer J Tuscher; Yuan Li; Michael Piatak; David O'Connor; Jeffrey D Lifson; Mario Roederer; Claes Ohlen
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

8.  An essential role for ectodomain shedding in mammalian development.

Authors:  J J Peschon; J L Slack; P Reddy; K L Stocking; S W Sunnarborg; D C Lee; W E Russell; B J Castner; R S Johnson; J N Fitzner; R W Boyce; N Nelson; C J Kozlosky; M F Wolfson; C T Rauch; D P Cerretti; R J Paxton; C J March; R A Black
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

9.  Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaques.

Authors:  Justin M Greene; Benjamin J Burwitz; Alex J Blasky; Teresa L Mattila; Jung Joo Hong; Eva G Rakasz; Roger W Wiseman; Kim J Hasenkrug; Pamela J Skinner; Shelby L O'Connor; David H O'Connor
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

10.  Allogeneic lymphocyte transfer in MHC-identical siblings and MHC-identical unrelated Mauritian cynomolgus macaques.

Authors:  Edward T Mee; Richard Stebbings; Joanna Hall; Elaine Giles; Neil Almond; Nicola J Rose
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

View more
  8 in total

Review 1.  Chimeric antigen receptor T-cell approaches to HIV cure.

Authors:  Anne-Sophie Kuhlmann; Christopher W Peterson; Hans-Peter Kiem
Journal:  Curr Opin HIV AIDS       Date:  2018-09       Impact factor: 4.283

2.  The Frequency of Vaccine-Induced T-Cell Responses Does Not Predict the Rate of Acquisition after Repeated Intrarectal SIVmac239 Challenges in Mamu-B*08+ Rhesus Macaques.

Authors:  Mauricio A Martins; Lucas Gonzalez-Nieto; Young C Shin; Aline Domingues; Martin J Gutman; Helen S Maxwell; Diogo M Magnani; Michael J Ricciardi; Núria Pedreño-Lopez; Varian K Bailey; John D Altman; Christopher L Parks; David B Allison; Keisuke Ejima; Eva G Rakasz; Saverio Capuano; Ronald C Desrosiers; Jeffrey D Lifson; David I Watkins
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

3.  In Vivo Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses.

Authors:  Sirish Khanal; Christine M Fennessey; Sean P O'Brien; Abigail Thorpe; Carolyn Reid; Taina T Immonen; Rodman Smith; Julian W Bess; Adrienne E Swanstrom; Gregory Q Del Prete; Miles P Davenport; Afam A Okoye; Louis J Picker; Jeffrey D Lifson; Brandon F Keele
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

4.  Preferential Small Intestine Homing and Persistence of CD8 T Cells in Rhesus Macaques Achieved by Molecularly Engineered Expression of CCR9 and Reduced Ex Vivo Manipulation.

Authors:  Matthew T Trivett; James D Burke; Claire Deleage; Lori V Coren; Brenna J Hill; Sumiti Jain; Eugene V Barsov; Matthew W Breed; Joshua A Kramer; Gregory Q Del Prete; Jeffrey D Lifson; Adrienne E Swanstrom; David E Ott
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

5.  Stem Cell-Derived Viral Antigen-Specific T Cells Suppress HIV Replication and PD-1 Expression on CD4+ T Cells.

Authors:  Mohammad Haque; Fengyang Lei; Xiaofang Xiong; Yijie Ren; Hao-Yun Peng; Liqing Wang; Anil Kumar; Jugal Kishore Das; Jianxun Song
Journal:  Viruses       Date:  2021-04-25       Impact factor: 5.048

6.  CXCR5-Dependent Entry of CD8 T Cells into Rhesus Macaque B-Cell Follicles Achieved through T-Cell Engineering.

Authors:  Victor I Ayala; Claire Deleage; Matthew T Trivett; Sumiti Jain; Lori V Coren; Matthew W Breed; Joshua A Kramer; James A Thomas; Jacob D Estes; Jeffrey D Lifson; David E Ott
Journal:  J Virol       Date:  2017-05-12       Impact factor: 6.549

7.  T-cell responses to KSHV infection: a systematic approach.

Authors:  Romin Roshan; Nazzarena Labo; Matthew Trivett; Wendell Miley; Vickie Marshall; Lori Coren; Elena M Cornejo Castro; Hannah Perez; Benjamin Holdridge; Eliza Davis; Rodrigo Matus-Nicodemos; Victor I Ayala; Raymond Sowder; Kathleen M Wyvill; Karen Aleman; Christine Fennessey; Jeffrey Lifson; Mark N Polizzotto; Daniel Douek; Brandon Keele; Thomas S Uldrick; Robert Yarchoan; Claes Ohlen; David Ott; Denise Whitby
Journal:  Oncotarget       Date:  2017-11-25

8.  CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.

Authors:  Mary S Pampusch; Hadia M Abdelaal; Emily K Cartwright; Jhomary S Molden; Brianna C Davey; Jordan D Sauve; Emily N Sevcik; Aaron K Rendahl; Eva G Rakasz; Elizabeth Connick; Edward A Berger; Pamela J Skinner
Journal:  PLoS Pathog       Date:  2022-02-07       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.